Resveratrol relieves gestational diabetes mellitus in mice through activating AMPK

Yao, Liangqi; Wan, Jipeng; Li, Hongyan; Ding, Jian; Wang, Yanyun; Wang, Xietong; Li, Mingjiang

doi:10.1186/s12958-015-0114-0

Cited by 75 publications

(86 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…; Yao et al . ). Furthermore, RESV improved maternal uterine arterial blood flow, reduced gestational weight gain and increased insulin sensitivity (Singh et al .…”

Section: Introductionmentioning

confidence: 97%

Maternal resveratrol administration protects against gestational diabetes‐induced glucose intolerance and islet dysfunction in the rat offspring

Brawerman

Kereliuk

Brar

et al. 2019

The Journal of Physiology

View full text Add to dashboard Cite

Key points Maternal resveratrol (RESV) administration in gestational diabetes (GDM) restored normoglycaemia and insulin secretion. GDM‐induced obesity was prevented in male GDM+RESV offspring but not in females. GDM+RESV offspring exhibited improved glucose tolerance and insulin sensitivity. GDM+RESV restored hepatic glucose homeostasis in offspring. Glucose‐stimulated insulin secretion was enhanced in GDM+RESV offspring. Abstract Gestational diabetes (GDM), the most common complication of pregnancy, is associated with adverse metabolic health outcomes in offspring. Using a rat model of diet‐induced GDM, we investigated whether maternal resveratrol (RESV) supplementation (147 mg kg–1 day–1) in the third week of pregnancy could improve maternal glycaemia and protect the offspring from developing metabolic dysfunction. Female Sprague–Dawley rats consumed a high‐fat and sucrose (HFS) diet to induce GDM. Lean controls consumed a low‐fat (LF) diet. In the third trimester, when maternal hyperglycaemia was observed, the HFS diet was supplemented with RESV. At weaning, offspring were randomly assigned a LF or HFS diet until 15 weeks of age. In pregnant dams, RESV restored glucose tolerance, normoglycaemia and improved insulin secretion. At 15 weeks of age, GDM+RESV‐HFS male offspring were less obese than the GDM‐HFS offspring. By contrast, the female GDM+RESV‐HFS offspring were similarly as obese as the GDM‐HFS group. Hepatic steatosis, insulin resistance, glucose intolerance and dysregulated gluconeogenesis were observed in the male GDM offspring and were attenuated in the offspring of GDM+RESV dams. The dysregulation of several metabolic genes (e.g. ppara, lpl, pepck and g6p) in the livers of GDM offspring was attenuated in the GDM+RESV offspring group. Glucose stimulated insulin secretion was also improved in the islets from offspring of GDM+RESV dams. Thus, maternal RESV supplementation during the third trimester of pregnancy and lactation induced several beneficial metabolic health outcomes for both mothers and offspring. Therefore, RESV could be an alternative to current GDM treatments.

show abstract

“…; Yao et al . ). Furthermore, RESV improved maternal uterine arterial blood flow, reduced gestational weight gain and increased insulin sensitivity (Singh et al .…”

Section: Introductionmentioning

confidence: 97%

Maternal resveratrol administration protects against gestational diabetes‐induced glucose intolerance and islet dysfunction in the rat offspring

Brawerman

Kereliuk

Brar

et al. 2019

The Journal of Physiology

View full text Add to dashboard Cite

show abstract

“…These animals typically present with glucose intolerance, insulin resistance, hyperglycemia, increased food intake, and increased weight gain during, but not prior to, pregnancy2223242526273031. However, several recent studies using the model, including our own, have been unable to reproduce this phenotype323337.…”

Section: Discussionmentioning

confidence: 96%

“…db/+ mice are heterozygous for a point mutation of the leptin receptor, which renders the receptor inactive20. While female mice appear normal in the virgin state, they develop glucose intolerance during pregnancy21222324252627. In addition, offspring of db/+ mice suffer similar consequences to children affected by GDM (obesity, diabetes in later life)2829, and db/+ mothers that are allowed to age after giving birth also show a phenotype that is reminiscent of post-pregnant mothers afflicted by GDM3031.…”

mentioning

confidence: 99%

Absence of a gestational diabetes phenotype in the LepRdb/+ mouse is independent of control strain, diet, misty allele, or parity

Plows

Broadhurst

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Treatment options for gestational diabetes (GDM) are limited. In order to better understand mechanisms and improve treatments, appropriate animal models of GDM are crucial. Heterozygous db mice (db/+) present with glucose intolerance, insulin resistance, and increased weight gain during, but not prior to, pregnancy. This makes them an ideal model for GDM. However, several recent studies have reported an absence of GDM phenotype in their colony. We investigated several hypotheses for why the phenotype may be absent, with the aim of re-establishing it and preventing further resources being wasted on an ineffective model. Experiments were carried out across two laboratories in two countries (New Zealand and China), and were designed to assess type of control strain, diet, presence of the misty allele, and parity as potential contributors to the lost phenotype. While hyperleptinemia and pre-pregnancy weight gain were present in all db/+mice across the four studies, we found no consistent evidence of glucose intolerance or insulin resistance during pregnancy. In conclusion, we were unable to acquire the GDM phenotype in any of our experiments, and we recommend researchers do not use the db/+ mouse as a model of GDM unless they are certain the phenotype remains in their colony.

show abstract

“…Conversely, a meta-analysis of 10 randomized controlled trials did not indicate a significant effect of resveratrol supplementation upon glucose level (41). The mechanism of action of resveratrol in the treatment of diabetes mellitus seems to be multifactorial; resveratrol may have antioxidant properties, increase AMPK activation, and increase internalization of glucose through modulating glucose transporter expression (98)(99)(100).…”

Section: Polyphenolsmentioning

confidence: 99%

The role of nutraceuticals in the prevention of cardiovascular disease

Sosnowska

Penson

Banach

2017

Cardiovasc. Diagn. Ther.

View full text Add to dashboard Cite

IntroductionCardiovascular disease (CVD) is common, indeed the majority of adults above sixty years of age will experience some manifestation of CVD. Based on data from 2012 and 2013, it has been estimated that CVD is responsible for 17.3 million deaths annually worldwide (1). Morbidity is also high, and in Europe, 200 billion Euros of healthcare expenditure is attributable to CVD (2). Risk factors for CVD can be categorized as modifiable and non-modifiable. Modifiable risk factors include obesity, hypertension, hyperlipidemia, diabetes mellitus, metabolic syndrome and lifestyle risk factors such as unhealthy diet, smoking and physical inactivity. Dietary factors are also important contributors to cardiovascular risk, either directly, or through their effects on other risk factors including hypertension, dyslipidemia and diabetes mellitus (3). Reduction of risk factors in the population, especially blood pressure reduction and lipid-lowering can have important impacts upon mortality from CVD (4).Protective effects against CVD have been demonstrated for several foods and dietary supplements (5) thus presenting new possibilities for population-level reduction of CVD risk. Evidence suggests that this approach is very promising. For example, in the PREDIMED observational study, participants in the highest quintile of polyphenol consumption had a relative risk of CVD of 54% compared to those in the lowest quintile (6). The aim of this review is to present an update on the most recent evidence relating to the use of nutraceuticals in the context of the prevention and treatment of CVD. Unfortunately, few studies have measured the associations between nutraceutical consumptions and "hard" outcomes such as mortality. Large randomized controlled trials are particularly rare, and thus there is a paucity of evidence in this area. Thus, our discussion will be largely focused on the effects of NutraceuticalsThe term "nutraceuticals" was introduced by Stephen DeFelice, founder and chairman of the Foundation for Innovation in Medicine, in 1989. A nutraceutical is defined as a "food, or parts of a food, that provide medical or health benefits, including the prevention and treatment of disease" (7). The definition encompasses medicinal products made from natural ingredients. Several classes of nutraceuticals have been proposed to have potential benefits in the treatment of CVD and the ones with the strongest evidence are briefly summarized below. Sterols/stanolsPlant sterols/stanols are phytosterols, and have been identified in a range of plant products including various fruits and vegetables, cereals, seeds and nuts. Their biological activity results from their molecular structural similarity to cholesterol (8). PolyphenolsPolyphenols are phytochemicals with widespread distribution in foods of plant origin. They are found in fruits, vegetables, cereal and legumes. Additionally, they are found in beverages produced from plant products such as tea, coffee, wine and cocoa. Polyphenols are structurally diverse, and over 8,000 have...

show abstract

Resveratrol relieves gestational diabetes mellitus in mice through activating AMPK

Cited by 75 publications

References 29 publications

Maternal resveratrol administration protects against gestational diabetes‐induced glucose intolerance and islet dysfunction in the rat offspring

Maternal resveratrol administration protects against gestational diabetes‐induced glucose intolerance and islet dysfunction in the rat offspring

Absence of a gestational diabetes phenotype in the LepRdb/+ mouse is independent of control strain, diet, misty allele, or parity

The role of nutraceuticals in the prevention of cardiovascular disease

Contact Info

Product

Resources

About